Ibnsina Pharma (EGX:ISPH)
Egypt · Delayed Price · Currency is EGP 12.05
-0.15 (-1.23%)
At close: Jun 25, 2026
Ibnsina Pharma Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Ibnsina Pharma stock has a consensus rating of "Strong Buy" and an average price target of E£17.26. The average 1-year stock price forecast is 43.24% higher than the current stock price, while the lowest is E£14.50 (+20.33%) and the highest is E£21.00 (+74.27%).
Price Target: E£17.26 (+43.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ibnsina Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 0 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 1 | 2 | 3 | 3 |
Financial Forecast
Revenue This Year
89.87B
from 76.60B
Increased by 17.33%
Revenue Next Year
101.19B
from 89.87B
Increased by 12.59%
EPS This Year
0.90
EPS Next Year
1.40
from 0.90
Increased by 55.56%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EGP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 91.7B | ||
| Avg | 89.9B | ||
| Low | 88.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 19.7% | ||
| Avg | 17.3% | ||
| Low | 15.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.90 | ||
| Avg | 0.90 | ||
| Low | 0.90 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | 55.6% | |
| Avg | 55.6% | |
| Low | 55.6% |